title: Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation.
abstract: The neutrophil superoxide (O2-)-producing capacity in 57 patients with chronic myeloproliferative disorders (MPDs) and eight patients with chronic myelomonocytic leukemia (CMML) was investigated. O2- release in neutrophils stimulated by chemotactic peptide was markedly increased in all types of chronic MPD, including chronic myelogenous leukemia in both chronic phase and blastic crisis, polycythemia vera, and essential thrombocythemia, but was normal in CMML, which is thought to be a myelodysplastic disorder rather than MPD. Increase in O2(-)-producing capacity in MPD was also observed when other receptor-mediated agonists such as interleukin-8 and concanavalin A were used, but not when phorbol ester, a direct activator of protein kinase C, was used as the triggering agonist of O2- release. Priming effects of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and tumor necrosis factor (TNF) on chemotactic peptide-induced O2- release was observed in all patients with MPD and CMML, though fold enhancement of priming effects was much less in MPD compared with normal subjects. In addition, the priming effects of TNF were less than those of GM-CSF in 10 cases, whereas the priming effects of TNF were consistently and markedly greater than those of GM-CSF in normal subjects. Tyrosine phosphorylation of 42-kDa protein stimulated by G-CSF, GM-CSF, and TNF was observed in CML neutrophils to be identical to that in normal neutrophils. Present results indicate specific potentiation of the receptor-mediated route of signaling that is linked to the respiratory burst and downregulated responsiveness to cytokines in neutrophils in patients with all types of chronic MPD, suggesting in vivo priming of patient neutrophils via certain mechanism by cytokines or related stimuli in these hematological disorders.
authors.affiliation: Department of Hematology, International Medical Center of Japan, Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Iki
authors.forename: A
authors.initials: A
authors.lastname: Yuo
authors.forename: M
authors.initials: M
authors.lastname: Yagisawa
authors.forename: E K
authors.initials: EK
authors.lastname: Inuo
authors.forename: Y
authors.initials: Y
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Usuki
authors.forename: A
authors.initials: A
authors.lastname: Urabe
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Kitagawa
authors.forename: A
authors.initials: A
authors.lastname: Togawa
authors.forename: F
authors.initials: F
authors.lastname: Takaku
mesh_terms: D003208:Concanavalin A / Q000494:pharmacology; D016207:Cytokines / Q000494:pharmacology*; D006801:Humans; D016209:Interleukin-8 / Q000494:pharmacology; D009196:Myeloproliferative Disorders / Q000378:metabolism* / Q000473:pathology; D018375:Neutrophil Activation / Q000187:drug effects; D009504:Neutrophils / Q000378:metabolism* / Q000473:pathology; D011956:Receptors, Cell Surface / Q000819:agonists / Q000378:metabolism*; D016897:Respiratory Burst; D015398:Signal Transduction; D013481:Superoxides / Q000378:metabolism*
chemical_list: D016207:Cytokines; D016209:Interleukin-8; D011956:Receptors, Cell Surface; D003208:Concanavalin A; D013481:Superoxides